Balancing Risk, Cost and Speed During Clinical Development While Still Maintaining Quality

Published: July 27, 2020, 2:30 p.m.

In this podcast, we talked with Thierry Cournez Vice President, BioReliance® End-to-End Solutions, MilliporeSigma. We discussed effective ways for emerging biotechs to collect material quickly and cost-effectively for pre-clinical and clinical studies. We also discussed managing the need to move quickly with cost and quality.